Patents Issued in May 12, 2016
  • Publication number: 20160129060
    Abstract: The invention relates to a composition for use in the treatment of neurobehavioral disorders, a Cannabis plant extract comprising Cannabinol preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from Cannabis sativa and/or Cannabis indica and/or Cannabis ruderalis and/or citrus fruits, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against sleeping disorders, in particular insomnia, and anxiety disorders including ADHD.
    Type: Application
    Filed: June 13, 2014
    Publication date: May 12, 2016
    Inventors: Dorothy Helen BRAY, Mario LAP, Alfredo Carlos DUPETIT
  • Publication number: 20160129061
    Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for preventing and treating non-alcoholic fatty liver disease, which comprises red ginseng concentrate having enhanced Compound K as an effective ingredient by using an enzyme conversion technique.
    Type: Application
    Filed: November 9, 2015
    Publication date: May 12, 2016
    Inventors: Se Hee Paek, Yong Ki Seo, Ji Hye Song, Byoung Seok Moon, Heung Sop Shin, Hwa Soo Shin
  • Publication number: 20160129062
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Application
    Filed: January 18, 2016
    Publication date: May 12, 2016
    Inventor: JOSH REYNOLDS
  • Publication number: 20160129063
    Abstract: The invention relates to a composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa comprising cranberry concentrate, urea, L-arginine, a buffer ensuring a pH value of the composition of 3.0 to 4.0, water and, optionally, additional active and/or auxiliary substances. The present invention also relates to a two-compartment blister pack containing the composition and to a kit comprising the two-compartment blister pack and an applicator fitting to the outlet channel of the blister pack easy to apply the composition to the desired areas.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 12, 2016
    Inventors: Marcus Malkmus, Kathrin Kortschak
  • Publication number: 20160129064
    Abstract: This invention relates to a method of treating metabolic syndrome and diabetes using a composition containing quercetin, vitamin B3, vitamin C, and a Bauhinia forficata extract.
    Type: Application
    Filed: January 20, 2016
    Publication date: May 12, 2016
    Inventor: Thomas Christian Lines
  • Publication number: 20160129065
    Abstract: The present invention relates to a composition for preventing and treating gastrointestinal diseases by using Litsea japonica, and specifically, to a composition for preventing and treating gastrointestinal diseases, containing essential oils extracted from Litsea japonica fruit as an active ingredient. According to the present invention, the essential oils extracted from Litsea japonica fruits (pure fruit, seed fruit, and seeds) and used as the active ingredient of the composition for preventing and treating gastrointestinal diseases have been confirmed to have excellent effects in an efficacy evaluation for relieving gastrointestinal diseases caused by Helicobacter pylori, which is a gastrointestinal disease factor, physical factors induced by stress, and chemical factors induced by indomethacin. Therefore, the essential oils extracted from Litsea japonica fruit (pure fruit, seed fruit, and seeds) are useful for preventing and treating gastrointestinal diseases caused by various factors.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 12, 2016
    Inventors: Ju-Hyun CHO, In-Jae PARK, Yong-Hwan JUNG, Goo-Hee CHOI, Weon-Jong YOON, Sung-Hwan PARK, Ji-Hyun YUN, Soon-Ok BAIK
  • Publication number: 20160129066
    Abstract: The present invention provides an all-natural, topical pain relief cream, with no artificial ingredients using Bentonite U.S.P. and sterile water U.S.P. as the foundation. The cream contains as active ingredients, one or more of menthol (regular or maximum strength), and salicin (methyl salicylate), with camphor and capsaicin as optional active ingredients. The vehicle includes coconut oil and lecithin to help retain the more volatile ingredients in with cream.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 12, 2016
    Inventors: Mario Medri, Judith Shewatjon
  • Publication number: 20160129067
    Abstract: Disclosed is use of an asparagus powder in medicines, food, and health foods for treatment of anxiety and depressive mental disorders, with active ingredients in the asparagus powder including: 15.0% or more of an asparagus saponin, 8% or more of a polysaccharide, 3.0% or more of a polyphenol, and 2.0% or more of a flavone.
    Type: Application
    Filed: January 22, 2014
    Publication date: May 12, 2016
    Inventors: YUNXIANG HUANG, LONG CHENG, QIPENG YUAN
  • Publication number: 20160129068
    Abstract: The present invention is related to a composition for relieving joint inflammation. The present invention is also related to a method for treatment of joint inflammation, comprising a step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition. By means of inhibiting the COX-2 and NF-?B expression through the composition or the pharmaceutical composition with specific ratio, the joint inflammation and swelling could be reduced and the osteoclasts proliferation could be decreased to mitigate bone erosion, osteoporosis and degenerative arthritis.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 12, 2016
    Inventor: Yu-Fang Ling
  • Publication number: 20160129069
    Abstract: A method for inducing a proliferation of dopaminergic cells in a subject in need, comprising: administering a herbal medicinal composition to a subject in need, wherein the herbal medicinal composition comprises: Ginseng Radix, Glycyrrhiza uralensis, Zingiber officinale Roscoe, Cinnamomum cassia Presl., and Scutellariae Radix.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 12, 2016
    Inventor: Chen-Yu LEE
  • Publication number: 20160129070
    Abstract: Compositions and methods for the treatment of cancer in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a GSSG and a carrier thereof. In an aspect, the carrier is a liposome. In a further aspect, the liposome is a positively charged liposome.
    Type: Application
    Filed: October 6, 2015
    Publication date: May 12, 2016
    Inventors: Xiangming Guan, Chandradhar Dwivedi, Teresa Seefeldt, Satya Sadhu
  • Publication number: 20160129071
    Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 12, 2016
    Inventors: Eric A.F. van Tol, Marieke H. Schoemaker, Gabriele Gross
  • Publication number: 20160129072
    Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 12, 2016
    Inventor: Lakhmir Chawla
  • Publication number: 20160129073
    Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.
    Type: Application
    Filed: November 17, 2015
    Publication date: May 12, 2016
    Inventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suarez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gomez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcon Cama, Osvaldo Reyes Acosta
  • Publication number: 20160129074
    Abstract: Disclosed herein are methods of formulating cyclosporin A Form 2.
    Type: Application
    Filed: January 14, 2016
    Publication date: May 12, 2016
    Inventors: Anuradha V. Gore, Prem Swaroop Mohanty, E. Quinn Farnes
  • Publication number: 20160129075
    Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.
    Type: Application
    Filed: November 4, 2015
    Publication date: May 12, 2016
    Inventors: Stanley Hazen, Zeneng Wang
  • Publication number: 20160129076
    Abstract: This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 12, 2016
    Inventors: Alyssa Panitch, John Eric Paderi, Shaili Sharma, Katherine Allison Stuart, Nelda Marie Vazquez-Portalatin
  • Publication number: 20160129077
    Abstract: A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.
    Type: Application
    Filed: June 13, 2014
    Publication date: May 12, 2016
    Inventors: Xitian Zhang, Fei Sun
  • Publication number: 20160129078
    Abstract: Compositions and methods for managing the growth, life cycle, functionality, or biological progression of cells, tissues, and organisms by introducing rhomboid proteins or peptides into the internal and external environment of the cells, tissues, and organisms. In particular, embodiments comprise compositions and methods for overcoming drug resistance in disease, and for sensitizing cells, tissues, and organisms to agents to treat disease, and methods for producing such compositions. The compositions and methods include rhomboid proteins, polypeptides, and/or peptides, and nucleic acids encoding such proteins, polypeptides, and/or and peptides, corresponding to the Arabidopsis At1g74130 or At1g25290 gene or human UBAC2 gene.
    Type: Application
    Filed: October 9, 2015
    Publication date: May 12, 2016
    Inventors: Kenton Ko, Joshua Powles
  • Publication number: 20160129079
    Abstract: The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 12, 2016
    Applicant: Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center
    Inventors: Zahava VADASZ, Elias TOUBI
  • Publication number: 20160129080
    Abstract: Patients with polypoidal choroidal vasculopathy receive a combination of both (i) a photodynamic therapy, such as verteporfin and (ii) a non-antibody VEGF antagonist.
    Type: Application
    Filed: June 18, 2014
    Publication date: May 12, 2016
    Inventor: Aaron OSBORNE
  • Publication number: 20160129081
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 12, 2016
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Publication number: 20160129082
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Application
    Filed: September 4, 2015
    Publication date: May 12, 2016
    Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
  • Publication number: 20160129083
    Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
    Type: Application
    Filed: January 19, 2016
    Publication date: May 12, 2016
    Inventors: Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
  • Publication number: 20160129084
    Abstract: The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Application
    Filed: March 6, 2014
    Publication date: May 12, 2016
    Inventors: Anthony O. CAGGIANO, Anindita GANGULY, Jennifer IACI, Tom PARRY
  • Publication number: 20160129085
    Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
    Type: Application
    Filed: October 2, 2015
    Publication date: May 12, 2016
    Inventor: Louis Hawthorne
  • Publication number: 20160129086
    Abstract: The present invention concerns methods and compositions for forming complexes of interferon-? with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-? and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (DDD) moiety from human protein kinase A or an anchor domain (AD) moiety from an A-kinase anchoring protein (AKAP). In more preferred embodiments, the interferon-antibody complex is more efficacious for treatment of cancer, asthma, Alzheimer's disease, multiple sclerosis or viral infection than interferon-? alone, antibody alone, or the combination of unconjugated interferon-? and antibody.
    Type: Application
    Filed: January 18, 2016
    Publication date: May 12, 2016
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Donglin Liu
  • Publication number: 20160129087
    Abstract: The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.
    Type: Application
    Filed: May 4, 2015
    Publication date: May 12, 2016
    Inventors: Michael Edward Christe, Thomas Andrew Hardy
  • Publication number: 20160129088
    Abstract: One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation comprises a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.
    Type: Application
    Filed: October 8, 2015
    Publication date: May 12, 2016
    Applicant: Dance Biopharm Inc.
    Inventors: John S. Patton, Ryan S. Patton, Mei-chang Kuo, Yehuda Ivri
  • Publication number: 20160129089
    Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a Somatostatin analogs having agonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.
    Type: Application
    Filed: June 13, 2014
    Publication date: May 12, 2016
    Inventor: George Tachas
  • Publication number: 20160129090
    Abstract: The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
    Type: Application
    Filed: November 12, 2015
    Publication date: May 12, 2016
    Inventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
  • Publication number: 20160129091
    Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.
    Type: Application
    Filed: December 28, 2015
    Publication date: May 12, 2016
    Inventors: Jeff Twidwell, Joel Buckley, Harold Hoium
  • Publication number: 20160129092
    Abstract: A method for the augmentation of immune function is described. The invention comprises a combination of ?-1,3 (4)-endoglucanohydrolase, ?-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species.
    Type: Application
    Filed: October 6, 2015
    Publication date: May 12, 2016
    Applicant: OMNIGEN RESEARCH, L.L.C.
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Publication number: 20160129093
    Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 12, 2016
    Inventors: James D. Crapo, A. Mario Q Marcondes, H. Joachim Deeg
  • Publication number: 20160129094
    Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 12, 2016
    Inventors: Mirjam H.M. HEEMSKERK, J.H. Frederik Falkenburg
  • Publication number: 20160129095
    Abstract: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
    Type: Application
    Filed: September 10, 2015
    Publication date: May 12, 2016
    Inventors: Randolph J. NOELLE, Cory L. Ahonen, Ross M. Kedl
  • Publication number: 20160129096
    Abstract: The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. a gastrin-17 peptide immunogen linked to a second peptidic alpha-helix coiled to the first alpha-helix, which peptide immunogen is any of (i) human gastrin-17 comprising the amino acid sequence of SEQ ID 1, or a fragment thereof comprising the amino acid sequence of SEQ ID 2, or at least the 4 N-terminal amino acids of SEQ ID 2; (ii) an analog of (i), preferably of rhesus monkey or murine origin; and/or (iii) a functionally active variant of any of (i) or (ii), with one, two, three or four point mutations in the amino acid sequence of SEQ ID 2. The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating gastrin dependent diseases.
    Type: Application
    Filed: May 16, 2014
    Publication date: May 12, 2016
    Applicant: TYG ONCOLOGY LTD.
    Inventor: Geert Mudde
  • Publication number: 20160129097
    Abstract: The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells. Cells can then be mixed with an unmethylated single stranded oligodeoxynucleotide chain adjuvant to formulate a vaccine and then administered to a subject. The vaccines can be autologous, allogeneic or hybrids thereof to the subject.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: JEREMY DELK, DONALD COHEN, JOHN YANNELLI
  • Publication number: 20160129098
    Abstract: It is disclosed herein that B cells, not dendritic cells or myeloid-derived populations, are primary human antigen presenting cells for plasmid DNA. Based on this finding, improved methods and compositions for administering DNA vaccines are disclosed. Specifically, DNA vaccines are co-administered with a B cell targeting agent, B-cell recruiting agent, or a monocyte or dendritic cell recruiting agent. To increase the immunogenicity of the DNA vaccines, the B cell targeting agent or B cell recruiting agent is administered at the same location where the DNA vaccine is administered. In contrast, the monocyte or dendritic cell recruiting agent can be administered in a different location, in order to recruit cells competing with the B cells for DNA uptake away from the location where the DNA vaccine is administered.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Douglas G. McNeel, Viswa T. Colluru
  • Publication number: 20160129099
    Abstract: There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a Reticulocyte-binding protein Homologue 5 (PfRH5) antigen having at least 90% identity with SEQ ID NO: 1, or a fragment thereof; or which comprise a viral vector that expresses PfRH5 antigen having at least 90% identity with SEQ ID NO: 2, or a fragment thereof.
    Type: Application
    Filed: November 9, 2015
    Publication date: May 12, 2016
    Inventors: Alexander Douglas, Simon Draper, Adrian Hill, Andrew Williams, Joseph Illingworth
  • Publication number: 20160129100
    Abstract: The present application provides methods of stimulating an immune response, such as a protective immune response against Treponema pallidum infection. Such methods utilize fragments of the Tp0751 protein (such as any of SEQ ID NOs: 3-10, those N-terminally truncated from amino acids 1 through 77, 1 through 114, or anywhere in between, e.g., those that start at any amino acid from 78 to 115). In some examples, a Tp0751 protein fragment has a mutated HEXXH site (HEXXH is the wild-type sequence). Also provided are the isolated soluble Tp0751 protein fragments that include a wild-type or mutated HEXXH site, as well as nucleic acids encoding such proteins and kits that include such proteins.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 12, 2016
    Applicant: UVic Industry Partnerships Inc.
    Inventors: Caroline E. Cameron, Rebecca M. Hof, Simon A. Houston, Martin John Boulanger
  • Publication number: 20160129101
    Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 12, 2016
    Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Philippe DENOEL, Pierre DUVIVIER, Carine GORAJ
  • Publication number: 20160129102
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Dan T. STINCHCOMB, Jorge E. OSORIO, Charalambos D. PARTIDOS, Joseph N. BREWOO
  • Publication number: 20160129103
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 12, 2016
    Applicants: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC., VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Publication number: 20160129104
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
  • Publication number: 20160129105
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 12, 2016
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
  • Publication number: 20160129106
    Abstract: This disclosure relates to methods for preparing a virosome preparation comprising viral envelope protein of at least two, preferably at least three, more preferably at least four, different enveloped viruses, as well as to virosomal preparations obtained thereby. The disclosure also relates to the use of the virosomal preparations, e.g., as a vaccine.
    Type: Application
    Filed: December 23, 2015
    Publication date: May 12, 2016
    Inventors: Wenyu Dong, Pieter Rijken, Mike Ugwoke
  • Publication number: 20160129107
    Abstract: A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 12, 2016
    Inventor: Thierry HEIDMANN
  • Publication number: 20160129108
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 12, 2016
    Applicant: MedImmune Limited
    Inventors: Kris SACHSENMEIER, Erin Sult, Carl Hay, Edmund Poon
  • Publication number: 20160129109
    Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, ?FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of ?FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
    Type: Application
    Filed: January 7, 2016
    Publication date: May 12, 2016
    Applicant: University of Maryland, Baltimore
    Inventors: Eduardo Davila, Koji Tamada